58885-60-2Relevant articles and documents
Self-Assembly of C3 Symmetric Rigid Macrolactams into Very Polar and Porous Trigonal Crystals
Marmin, Thomas,Dory, Yves L.
, p. 6707 - 6711 (2019)
Cyclohexane and cyclotri-β-alanyl have been used as scaffolds for the design of new C3-symmetric rings incorporating conjugated alkenes and dienes. All three C3-symmetric lactams share the same triangular shape and their crystal system is trigonal. They all belong to the R3 space group, R3m, R3 and R3c, for the increasingly large 12-, 18- and 24-membered rigid rings, respectively. All lactams stack on top of each other, through H-bonds and van der Waals noncovalent interactions, leading to endless supramolecular cylinders and tubes. The largest member of the family leads to tubes, the central pores of which is wide enough to let water in. A common feature of all the lactams is their very large dipole, of around 9 D, according to DFT calculations. Surprisingly, all the resulting cylinders and tubes pack side by side in the crystals, with all the dipoles pointing to the same direction. As a result, all three crystals are anisotropic and appear to be the first members of a new kind of highly polar crystals.
Asymmetric total synthesis of novel pentacyclic indole alkaloid, kopsiyunnanine E, isolated from Kopsia arborea
Kitajima, Mariko,Murakami, Yosuke,Takahashi, Nobuaki,Wu, Yuqiu,Kogure, Noriyuki,Zhang, Rong-Ping,Takayama, Hiromitsu
, p. 5000 - 5003 (2014)
A new pentacyclic indole alkaloid, kopsiyunnanine E, was isolated from Yunnan Kopsia arborea, and its structure, which was inferred from spectroscopic data, was established by a 16-step asymmetric total synthesis that proved that the natural alkaloid was not enantiomerically pure.
Optimization of Naphthyridones into Selective TATA-Binding Protein Associated Factor 1 (TAF1) Bromodomain Inhibitors
Bamborough, Paul,Chung, Chun-Wa,Clegg, Michael A.,Craggs, Peter D.,Demont, Emmanuel H.,Gordon, Laurie J.,Humphreys, Philip G.,Liwicki, Gemma M.,Phillipou, Alex,Prinjha, Rab K.,Theodoulou, Natalie H.,Tomkinson, Nicholas C. O.
supporting information, p. 1308 - 1317 (2021/08/24)
Bromodomain containing proteins and the acetyl-lysine binding bromodomains contained therein are increasingly attractive targets for the development of novel epigenetic therapeutics. To help validate this target class and unravel the complex associated biology, there has been a concerted effort to develop selective small molecule bromodomain inhibitors. Herein we describe the structure-based efforts and multiple challenges encountered in optimizing a naphthyridone template into selective TAF1(2) bromodomain inhibitors which, while unsuitable as chemical probes themselves, show promise for the future development of small molecules to interrogate TAF1(2) biology. Key to this work was the introduction and modulation of the basicity of a pendant amine which had a substantial impact on not only bromodomain selectivity but also cellular target engagement.
NOVEL IMIDAZOPYRAZINE DERIVATIVES
-
Page/Page column 51; 191-192, (2021/12/31)
The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein Rx and R3 to R5 are as described herein (formula (I)) or pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
